Company intelligence / Profile preview

CamDiab

Cambridge, England, United Kingdomcamdiab.com ↗

Ownership: Private
Development stage: Commercial

Overview

The company’s lead product, CamAPS FX, has demonstrated clinical benefit by maintaining blood glucose within a healthy range for people with type 1 diabetes—including children and pregnant women. In a randomized trial, over 70% of children maintained healthy glucose levels for a full day. The app has been used by more than 27,000 people across at least 15 countries following regulatory approvals in Europe and Australia; it received FDA clearance in May 2024.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: DeviceNon-pharmacological therapy
Industry: Digital Health Medical Devices

Partnerships

AbbottYpsomed

Beyond the preview

Go deeper on CamDiab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CamDiab.

Explore the full profile